关于中广核核技术发展股份有限公司 7信会计师事务所(特殊普通合伙) HINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANT "的"的""" "" " " " " 此码用于证明该审计报告是否由具有执业许可的会计师事务所出 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" 进行查 中文AT 7W 目 录 第1 - 2 页 ● 关于中广核核技术发展股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 第 1 - 11 页 中广核核技术发展股份有限公司股份有限公司 o 2023 年度非经营性资金占用及其他关联资金往 来情况汇总表 非经营性资金占用及其他关联资金往来情况的专项报告 2023 年度 信会师报字[2024]第 ZI10301 号 关于中广核核技术发展股份有限公司 非经营性资金占用及其他关联资金往来情况的专项报告 信会师报字[2024]第 ZI10301 号 中广核核技术发展股份有限公司全体股东: 我们审计了中广核核技术发展股份有限公司(以下简称"中广核 技")2023年度的财务报表,包括 2023年 12月 ...

证券代码：000881 证券简称：中广核技 公告编号：2024-025 中广核核技术发展股份有限公司 关于确认 2023 年度日常关联交易和预计 2024 年度 日常关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 本次关联交易是预计中广核核技术发展股份有限公司（以下简称"公司"或"中广 核技"，含控股子公司）2024 年度日常关联交易的基本情况，主要包括公司与关联 方之间金融服务、采购销售、接受与提供劳务、租赁等事项。 公司第十届董事会第十五次会议于 2024 年 4 月 25 日召开，审议通过了《关于 确认 2023 年度日常关联交易和预计 2024 年度日常关联交易的议案》。董事会审议 上述事项时，关联董事李勇、盛国福、文志涛、何祖元、慕长坤、吴远明进行了回 避表决，其余 3 名董事一致同意该议案，符合《公司章程》及有关规定。第十届董 事会审计委员会 2024 年第一次会议和独立董事专门会议 2024 年第二次会议对该议 案进行了前置审核，同意提交董事会审议。 根据日常经营需要，2024 ...

页: 1/320 版次: 4 CGNNT 公司会计核算管理制度 067-GN-P-MC-D11-117 中广核GOCGN 中广核核技术发展股份有限公司 CGN Nuclear Technology DevelopmentCo. Ltd. 管理制度 MANAGEMENT SYSTEM 责任部门:财务共享中心 相关信息:A 类制度 公司会计核算管理制度 录 H 第一章 总则………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 10 目的、依据和适用范围 . 1.1 1.2 会计基本假设和基础 1.3 会计信息质量要求 1.4 会计要素计量属性……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 12 第二章 资产 . 资产的定义和确认要求及分类 2.1 2.2 货币资金的定义和核算要求 2.3 金融资产 . ...

证券代码：000881 证券简称：中广核技 公告编号：2024-031 中广核核技术发展股份有限公司 关于 2023 年度计提信用及资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 2024 年 4 月 25 日，中广核核技术发展股份有限公司（以下简称"公司"） 第十届董事会第十五次会议审议通过了《关于 2023 年信用及资产减值准备计提 及转回的议案》。现将具体情况公告如下： 一、计提减值准备情况概述 （一）计提减值准备的原因 为更加真实、准确反映公司截至 2023 年 12 月 31 日的财务状况、资产价值 情况，根据《企业会计准则》《深圳证券交易所股票上市规则》《会计监管风险 提示第 8 号-商誉减值》以及公司会计政策、会计估计的相关规定，公司对 2023 年末应收账款、其他应收款、长期应收款、存货、固定资产、无形资产以及商誉 等各类资产进行了减值测试，对各类应收款项回收的可能性、存货的可变现净值、 固定资产、无形资产以及商誉的可收回金额等进行了充分的评估和分析，拟对部 分资产计提减值准备。 （二）本次计提减值损失的范围、总金额和拟计 ...

Financial Performance - The company reported a significant asset restructuring at the beginning of the year, enhancing its operational capabilities in nuclear technology applications[16]. - The company's operating revenue for 2023 was ¥6,352,518,944.55, a decrease of 8.53% compared to ¥6,944,907,174.49 in 2022[19]. - The net profit attributable to shareholders was a loss of ¥737,163,932.18, representing a decline of 469.33% from a profit of ¥198,751,228.01 in the previous year[19]. - The net cash flow from operating activities decreased by 34.13% to ¥371,271,537.71 from ¥563,624,947.09 in 2022[19]. - The diluted earnings per share for 2023 was -¥0.7797, compared to ¥0.2102 in 2022, marking a decline of 469.35%[20]. - Total assets at the end of 2023 were ¥11,283,404,643, down 5.76% from ¥11,972,423,061 at the end of 2022[20]. - The net assets attributable to shareholders decreased by 11.71% to ¥5,586,012,022 from ¥6,326,079,639 in 2022[20]. - The company reported a significant increase in non-recurring losses, with total non-recurring gains and losses amounting to ¥223,478,588.64 in 2023, down from ¥265,787,727.96 in 2022[26]. Business Operations and Strategy - The main business has expanded to include R&D and manufacturing of electronic accelerators, special waste treatment, irradiation processing services, new materials R&D and manufacturing, and healthcare services[16]. - The company is engaged in the research and development of electronic accelerators and new materials, focusing on applications in food preservation, sterilization, and environmental remediation[30]. - The company is expanding its market presence through strategic partnerships and collaborations in the healthcare and environmental sectors[41]. - The company aims to enhance its operational efficiency by adopting a sales-based production model, aligning production with market demand[41]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[41]. Market Trends and Industry Insights - The electronic accelerator market for material modification is experiencing a downward trend due to a slowdown in downstream industry growth, but demand for electronic accelerators in food, medical, and environmental sectors is expected to increase steadily in the future[32]. - The proton therapy market in China is still in its early stages, with only 8 operational centers compared to 128 globally, indicating significant growth potential as the country plans to add 8 more proton therapy systems for social medical institutions[37][38]. - The domestic modified polymer materials industry is facing intense competition in low-end products and overcapacity, but the "14th Five-Year Plan" aims to enhance the domestic production of high-end modified materials, accelerating the localization process[36]. - The irradiation sterilization market is shifting from traditional chemical methods to more effective irradiation methods, with increasing consumer demand for food quality driving this transition[32]. - The market for radioactive isotope drugs is rapidly developing in China, although it is still in its infancy, with a reliance on imports; recent government policies are expected to promote growth in this sector[39]. Research and Development - The company is investing in R&D for new technologies, including biodegradable materials and advanced wastewater treatment solutions[50]. - The company has 151 R&D personnel dedicated to the development of industrial electron accelerators, with 245 authorized patents, including 21 invention patents[64]. - The company reported a decrease in R&D investment, amounting to ¥328,572,159.33 in 2023, a decrease of 4.38% compared to ¥343,632,316.47 in 2022[92]. - R&D expenditure accounted for 5.17% of operating revenue, an increase of 0.22 percentage points from 4.95% in the previous year[92]. Regulatory and Compliance - The company has established an independent financial accounting department and maintains a separate accounting system, ensuring no funds are occupied by the controlling shareholder[151]. - The company is committed to compliance management and has revised its compliance management system to enhance risk prevention capabilities[147]. - The company has signed a binding contract to sell its stake in Jiangsu Triangle Delta, resolving industry competition issues[154]. Corporate Governance - The company held 7 shareholder meetings, 12 board meetings, and 6 supervisory meetings during the reporting period[146]. - The board of directors held 12 meetings during the reporting period, approving 105 important proposals and reviewing 18 reports[197]. - The independent directors effectively fulfilled their responsibilities and maintained the rights of shareholders, particularly minority shareholders[198]. - The company is committed to enhancing its operational efficiency through the implementation of various strategic initiatives[197]. Future Outlook - The company expects a revenue guidance of 12 billion RMB for the fiscal year 2024, indicating a projected growth of 20%[160]. - The company plans to increase R&D investment and accelerate the transformation of scientific achievements in 2024 to drive high-quality development[75]. - The overall market outlook remains positive, with anticipated industry growth of 10% in the next fiscal year[159].

中广核核技术发展股份有限公司 独立董事 2023 年度述职报告（刘澄清） 2023 年度，本人作为中广核核技术发展股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章和规范性文件以及《公司 章程》《独立董事工作制度》的有关规定，本着诚信、勤勉、尽责的工作态度，有效履行了独立 董事职责，忠实行使了独立董事权利，切实维护了股东尤其是中小股东的合法权益，充分发挥了 独立董事应有的作用。现将 2023 年度独立董事履职情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 本人刘澄清，1955 年生，2017 年 1 月 24 日至 2023 年 1 月 18 日任公司独立董事及董事会 提名委员会主任委员、战略委员会、审计委员会、薪酬委员会委员。因任期届满，于 2023 年 1 月 19 日召开的股东大会后离任公司独立董事。本人在法律方面具有丰富经验，曾任深圳对外经 济律师事务所主任，英国 Linklaters Paines 交流律师，深圳法制报法律部 ...

中德证券有限责任公司 关于中广核核技术发展股份有限公司 2023 年度募集资金存放与使用情况的核查意见 公司募集资金投资项目由公司总经理负责组织实施，投资项目按公司报告书 承诺的计划进度实施，公司财务部负责资金的调度和安排，公司财务部对募集资 金的使用情况设立台账，详细反映募集资金的支出情况和投入情况。公司内部审 计部门至少每季度对募集资金的存放与使用情况检查一次，并及时向审计委员会 报告检查结果。 （二）募集资金的专户存储与监管情况 1、募集资金专户存储三方监管协议情况 中德证券有限责任公司（以下简称"中德证券"、"独立财务顾问"）作为 中广核核技术发展股份有限公司（原名为"中国大连国际合作（集团）股份有限 公司"，以下简称"中广核技"、"上市公司"或"公司"）向中广核核技术应 用有限公司等发行股份购买资产并募集配套资金暨关联交易的独立财务顾问及 主承销商，根据《上市公司重大资产重组管理办法》《上市公司并购重组财务顾 问业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》和《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等有关规定对上市公司 202 ...

证券代码：000881 证券简称：中广核技 公告编号：2024-030 中广核核技术发展股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023年年度股东大会。 本次股东大会的召开符合《公司法》《上市公司股东大会规则》《深圳证券交 易所股票上市规则》等有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。 4、会议召开的日期、时间： （1）现场会议召开日期、时间：2024 年 5 月 17 日（星期五）下午 2:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2024 年 5 月 17 日上午 9:15 至 9:25、9:30 至 11:30、下午 1:00 至 3:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年5 月 17 日上午 9:15 至下午 3:00 期间的任意时间。 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 公司将通过深圳证券交易所交易系统和互联 ...

《中广核核技术发展股份有限公司公司章程》修订对照表 说明：旧版被修改内容以蓝字标识，被删除内容以蓝字加删除线标识；新版对应修改内容以红字标识，新增内容以红字加下划线标识。 | 修订前 | 修订后 | 说明（依据/原因等） | | --- | --- | --- | | 第十二条 在公司中，根据《中国共产党章程》的规定，设 | 第十二条 在公司中，根据《中国共产党章程》的规定，设 | 对条款进行适应性调整。 | | 立中国共产党的组织，开展党的活动。党委发挥领导作 | 立中国共产党的组织，开展党的活动。公司建立党的工作 | | | 用，把方向、管大局、保落实。公司建立党的工作机构， | 机构，配备足够数量的党务工作人员，保障党组织的工作 | | | 配备足够数量的党务工作人员，保障党组织的工作经费， | 经费，为党组织的活动提供必要条件。 | | | 为党组织的活动提供必要条件。 | | | | 第七十条 在年度股东大会上，董事会、监事会应当就其过 | 第七十条 在年度股东大会上，董事会、监事会应当就其过 | 根据《上市公司独立董事管理办 | | 去一年的工作向股东大会作出报告。每名独立董事也应作 | 去一年的 ...

Financial Performance - The company's revenue for Q1 2024 was ¥1,309,795,211.41, representing a 6.81% increase compared to ¥1,226,257,155.66 in the same period last year[5] - The net loss attributable to shareholders was ¥65,181,223.29, a significant increase of 153.27% from a loss of ¥25,735,870.78 in the previous year[5] - The basic and diluted earnings per share were both -¥0.0689, reflecting a decrease of 153.31% from -¥0.0272 in the previous year[5] - Net loss for Q1 2024 was CNY 62,597,662.69, compared to a net loss of CNY 22,072,604.24 in Q1 2023, indicating a significant decline in profitability[20] - The company reported a total comprehensive loss of CNY 62,438,740.69 for Q1 2024, compared to a loss of CNY 29,206,761.51 in the same period last year[20] Cash Flow - The net cash flow from operating activities was negative at ¥38,042,141.21, a decline of 456.31% compared to a positive cash flow of ¥10,676,777.73 in the same period last year[5] - The cash received from operating activities decreased by 53.40% to ¥172,451,891.82, mainly due to a reduction in international trade receipts[12] - Operating cash flow for the current period was -38,042,141.21 CNY, a decrease from 10,676,777.73 CNY in the previous period[22] - Total cash inflow from operating activities was 1,494,279,905.78 CNY, down from 1,625,927,347.96 CNY year-over-year[22] - Cash outflow from operating activities totaled 1,532,322,046.99 CNY, compared to 1,615,250,570.23 CNY in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,059,510,900.39, down 1.98% from ¥11,283,404,643.67 at the end of the previous year[5] - Total current assets decreased from 6,374,725,270.24 CNY to 6,158,396,201.92 CNY, a decline of approximately 3.38%[16] - Total liabilities decreased to CNY 5,102,052,918.54 from CNY 5,253,602,360.01, representing a decline of about 2.9%[18] - The company's total equity decreased to CNY 5,957,457,981.85 from CNY 6,029,802,283.66, a decrease of approximately 1.2%[18] Investments - The company's long-term equity investments increased by 86.91% to ¥8,262,153.36, primarily due to a new investment of ¥4 million in a subsidiary[8] - Long-term equity investments rose from 4,420,377.44 CNY to 8,262,153.36 CNY, an increase of approximately 87.80%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 46,480[14] - The largest shareholder, China General Nuclear Power Technology Application Co., Ltd., holds 27.98% of shares, totaling 264,494,398 shares[14] - There are no changes in the participation of major shareholders in margin trading or securities lending[14] - The total number of preferred shareholders is not applicable[15] Operating Costs and Expenses - Total operating costs for Q1 2024 were CNY 1,397,561,395.19, up from CNY 1,289,111,272.36 in the same period last year, reflecting a year-over-year increase of 8.4%[19] - Research and development expenses for Q1 2024 were CNY 42,425,323.66, compared to CNY 37,975,849.50 in Q1 2023, reflecting an increase of 11.5%[19] Financing Activities - The company obtained new borrowings amounting to ¥769,278,847.01, a 74.32% increase compared to ¥441,303,232.73 in the previous year[12] - Cash inflow from financing activities was 769,278,847.01 CNY, significantly higher than 441,303,232.73 CNY in the previous period[23] - Net cash flow from financing activities improved to 181,523,429.60 CNY from -154,477,316.02 CNY year-over-year[23] Other Information - The company has not disclosed any new strategies or future outlook in the provided documents[15] - The company did not undergo an audit for the first quarter report[24]